CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 44 enrolled
Drug / intervention
CG2001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07038941
NCT07038941Phase 1Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of Single and Multiple Doses of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

Beijing Dayspring Pharmaceutical Technology Co., Ltd·interventional·Posted Jun 26, 2025·Updated Jun 26, 2025

In Brief

A Phase 1 clinical trial evaluating CG2001 and Placebo foam for Male Pattern of Hair Loss, Androgenic Alopecia and Androgenetic Alopecia (AGA). Completed, enrolled 44 participants across 1 site.

Detailed Summary

This study is testing CG2001, a new medicine that is applied as a light foam to the scalp and is being developed to treat male-pattern hair loss (androgenetic alopecia). The main goals are to find out: 1. Whether single and repeated daily doses of CG2001 are safe and well-tolerated 2. How much of the drug, if any, enters the bloodstream (pharmacokinetics)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMale Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
20252026
First PostedJun 26, 2025
Enrollment StartMar 19, 2024
Primary CompletionJun 2, 2024
TodayJul 1, 2026
Enrollment to primary: 2 monthsPosted 1.0 years ago

Interventions

CG2001drug

combination of minoxidil and finasteride

Placebo foamdrug

Placebo foam